AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16839836
Drug: 20% lipid/heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% lipid/heparin infusion at a rate of 1.5 mL/min for 6 hours
Trial: 16839836
Drug: Saline/heparin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline/heparin infusion at a rate of 1.5 mL/min for 6 hours
Trial: 10706957
Drug: Bicomponent acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicomponent acellular vaccine (pertussis toxin and filamentous hemagglutinin)
Trial: 10706957
Drug: Monocomponent acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monocomponent acellular vaccine (pertactin)
Trial: 9305674
Drug: Ribavirin combined
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin combined with alpha interferon (3 million units three times weekly for 6 months)
Trial: 9529766
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen treatment
Trial: 29253747
Drug: 15 mg/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg/d of methylprednisolone (group T1, n=17)
Trial: 29253747
Drug: 15 mg/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg/d of methylprednisolone at consent and 100 mg/2 h until kidney harvest (group T2, n=17)
Trial: 29092730
Drug: Clopidogrel generic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel generic 75 mg
Trial: 29092730
Drug: Clopidogrel reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel reference 75 mg
Trial: 8566257
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized E2
Trial: 1662191
Drug: ITRA-PEL (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITRA-PEL (2 x 100 mg once daily)
Trial: 1662191
Drug: ITRA-PEG (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITRA-PEG (4 x 50 mg once daily)
Trial: 6125185
Drug: Pindolol 20
RxNorm normalized name: pindolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol 20 mg
Trial: 30520216
Drug: Whey/guar preload
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey/guar preload (150 mL containing 17 g whey protein plus 5 g guar)
Trial: 24472156
Drug: Dihydroartemisinin-piperaquine (DP)
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (DP) paediatric tablets
Trial: 22948132
Drug: Cabergoline 0.25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 0.25mg for 8 days from the day of HCG administration
Trial: 20718766
Drug: r-hPRL (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-hPRL (60 μg/kg) administered subcutaneously every 12 h for 28 days (Study 1)
Trial: 20718766
Drug: r-hPRL (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-hPRL (60 μg/kg) administered every 12 h for 7 days (Study 2)
Trial: 20718766
Drug: r-hPRL (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-hPRL (60 μg/kg) administered daily for 7 days (Study 2)
Trial: 20718766
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered for 7 days (Study 2)
Trial: 17951067
Drug: 4 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/d curcumin
Trial: 17951067
Drug: 1 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/d curcumin
Trial: 15664003
Drug: Menatetrenone (MK-4)
RxNorm normalized name: menatetrenone
DrugBank: Menatetrenone (DB12148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menatetrenone (MK-4) 45 mg, ergocalciferol (vitamin D2) 1000 IU, calcium 600 mg daily for 2 years
Trial: 7726651
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg gemeprost (Cergem)
Trial: 2024813
Drug: Dexamethasone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.5 mg/kg/day for 3 days)
Trial: 19614965
Drug: Prednisolone (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (150 mg)
Trial: 14688699
Drug: Enoxaparin 1
RxNorm normalized name: ENOXAPARIN 100MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 1 mg/kg twice daily (n = 21)
Trial: 14688699
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin (n = 20)
Trial: 8825016
Drug: Ocuguard (broad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocuguard (broad spectrum antioxidant capsule)
Trial: 28566688
Drug: Low-dose HDM
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose HDM specific sublingual immunotherapy (n = 29)
Trial: 28566688
Drug: High-dose HDM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose HDM specific sublingual immunotherapy (n = 26)
Trial: 26187555
Drug: Interferon-based therapy
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-based therapy for 12 weeks
Trial: 20604775
Drug: Conventional cytology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cytology (CC) in NETHCON
Trial: 20604775
Drug: Conventional cytology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cytology (CC) in NTCC
Trial: 16700881
Drug: Furosemide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (20 mg/day)
Trial: 16700881
Drug: ACEI (imidapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI (imidapril 5 mg/day)
Trial: 16700881
Drug: ACEI (imidapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI (imidapril 5 mg/day) + Spironolactone (25 mg/day)
Trial: 16700881
Drug: ACEI (imidapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI (imidapril 5 mg/day) + Furosemide (20 mg/day)
Trial: 12699450
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment (Genotropin, 0.8 IU daily for 1 month, then 1.6 IU daily for 5 months)
Trial: 1465036
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation alone (500 mg/day)
Trial: 6146570
Drug: Long-term maintenance
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term maintenance training in patients on beta-blocker therapy
Trial: 29176359
Drug: Virtual intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual intravenous simulator
Trial: 22067902
Drug: Ibandronate 150
RxNorm normalized name: ibandronate 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 150 mg oral monthly
Trial: 18497717
Drug: Dialectical behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical behavior therapy for Substance Abusers (DBT-SAB)
Trial: 11792604
Drug: Oral ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibandronate (doses: 0.25, 0.50, 1.0, 2.5, or 5.0 mg daily)
Trial: 11012955
Drug: Sedation protocol
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedation protocol with rectal midazolam (0.5 mg x kg(‐1)) and S‐(+)‐ketamine (5 mg x kg(‐1)) plus i.v. supplementation (20+/‐10 microg x kg(‐1) x min(‐1) S‐(+)‐ketamine and 4+/‐2 microg x kg(‐1) x min(‐1) midazolam)
Trial: 8787886
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg genaconazole (racemate)
Trial: 8787886
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg or 200 mg genaconazole (RR enantiomer)
Trial: 8787886
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of 14C-labeled genaconazole
Trial: 1449110
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 2'-deoxycoformycin (dCF) and adenine arabinoside (ara-A)
Trial: 4016828
Drug: Wax-matrix iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wax-matrix iron preparation
Trial: 4016828
Drug: Sustained-release iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release iron preparation
Trial: 26893170
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral melatonin
Trial: 29027815
Drug: l‐carnosine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l‐carnosine (800 mg/day in 2 divided doses)
Trial: 18160247
Drug: Other chemotherapeutic
RxNorm normalized name: Other chemotherapeutics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other chemotherapeutic agents (OC)
Trial: 14628178
Drug: Flupenthixol decanoate
RxNorm normalized name: flupenthixol decanoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupenthixol decanoate (10 mg, injected every second week for 24 weeks)
Trial: 14628178
Drug: Flupenthixol decanoate
RxNorm normalized name: flupenthixol decanoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupenthixol decanoate (10 mg) in male patients
Trial: 14628178
Drug: Flupenthixol decanoate
RxNorm normalized name: flupenthixol decanoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupenthixol decanoate (10 mg) in female patients
Trial: 7670929
Drug: Human leukocyte
RxNorm normalized name: Human leukocyte antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human leukocyte interferon-alpha (2 x 10(6) IU/g)
Trial: 7670929
Drug: Podophyllotoxin 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Podophyllotoxin 0.5% in hydrophilic cream
Trial: 2189027
Drug: Standard Triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Triple Therapy (Hydrochlorothiazide + Propranolol + Hydralazine)
Trial: 7005629
Drug: Levamisole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (2.5 mg/kg orally on two consecutive days each week for 26 weeks)
Trial: 31082942
Drug: Cytoreductive nephrectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive nephrectomy in combination with sunitinib
Trial: 26134359
Drug: (1→3)‐β‐d‐glucan (BDG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (1→3)‐β‐d‐glucan (BDG) assay with cutoff positivity ≥80 pg/mL
Trial: 26134359
Drug: Candida albicans
RxNorm normalized name: Candida Albicans
DrugBank: Candida albicans (DB10429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candida albicans germ tube antibody (CAGTA) assay with cutoff positivity ≥1/160
Trial: 26134359
Drug: BDG and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDG and CAGTA kinetics in IC patients treated with antifungals
Trial: 26134359
Drug: Confounding factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Confounding factors (amoxicillin–clavulanate, piperacillin–tazobactam treatments, recent surgery, Gram‐positive bloodstream infection, renal replacement therapy, enteral nutrition)
Trial: 19470696
Drug: Tipifarnib 600
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tipifarnib 600 mg orally twice a day for the first 21 consecutive days in 28-day cycles
Trial: 15209646
Drug: Acetaminophen 650
RxNorm normalized name: acetaminophen 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650 mg four times a day (qid)
Trial: 15209646
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered qid with acetaminophen as needed (prn)
Trial: 2535953
Drug: Radiation plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation plus ACNU (30 mg/m2 x 4 times during irradiation)
Trial: 792861
Drug: Mianserin ('Bolvidon')
DrugBank: Mianserin (DB06148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin ('Bolvidon') at an average dose of 40 mg a day
Trial: 792861
Drug: Imipramine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine at an average dose of 100 mg a day
Trial: 31488314
Drug: Roluperidone 32
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roluperidone 32 mg
Trial: 31488314
Drug: Roluperidone 64
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roluperidone 64 mg
Trial: 30886125
Drug: Inhaled nemiralisib
RxNorm normalized name: Nemiralisib
DrugBank: Nemiralisib (DB16253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nemiralisib (0.1‐6.4 mg) for up to 14 days
Trial: 30886125
Drug: Inhaled nemiralisib
RxNorm normalized name: Nemiralisib
DrugBank: Nemiralisib (DB16253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nemiralisib (2 mg, once daily)
Trial: 30886125
Drug: Inhaled nemiralisib
RxNorm normalized name: Nemiralisib
DrugBank: Nemiralisib (DB16253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nemiralisib
Trial: 30045355
Drug: Intranasal Ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Ketamine (1 mg/kg)
Trial: 30045355
Drug: Intranasal Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal Fentanyl (1.5 μg/kg)
Trial: 25913538
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment as usual
Trial: 24282229
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (40 mg, 3 times per day)
Trial: 8385741
Drug: Placebo (identical-appearing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical-appearing tablets)
Trial: 15197285
Drug: Enhanced psychosocial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced psychosocial treatment (comprehensive intervention with counseling, support, and consultation)
Trial: 15197285
Drug: Enhanced psychosocial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced psychosocial treatment
Trial: 11773290
Drug: Systemic adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic adjuvant therapy (including chemotherapy and tamoxifen)
Trial: 2657424
Drug: Intrathecal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal infusion of baclofen
Trial: 25790022
Drug: EPA/DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA/DHA supplementation (650 mg of eicosapentaenoic acid and docosahexaenoic acid)
Trial: 25790022
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 g of margarine daily without EPA/DHA)
Trial: 18499184
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (200 U intradetrusor injection)
Trial: 10966968
Drug: Combined drug
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined drug administration
Trial: 7825505
Drug: 0.3% S-1033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% S-1033 solution
Trial: 7825505
Drug: 0.4% S-1033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% S-1033 solution
Trial: 7825505
Drug: 0.3% S-1033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% S-1033 solution (multiple-dose study)
Trial: 7825505
Drug: Vehicle solution
RxNorm normalized name: compounding vehicle solution sugar free no. 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle solution (control)
Trial: 29270836
Drug: MCP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCP block (20 ml of ropivacaine 0.2%)
Trial: 29270836
Drug: ISP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISP block (20 ml of ropivacaine 0.2%)
Trial: 26284410
Drug: Dexamethasone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (10 mg intravenously before anesthetic induction)
Trial: 18484560
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (n=16)
Trial: 17699258
Drug: Low-dose RATG
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose RATG (0.5 mg/kg per d) plus basiliximab (20 mg 4 d apart)
Trial: 17699258
Drug: Standard-dose RATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose RATG (2 mg/kg per d)
Trial: 9099188
Drug: 1 microgram
RxNorm normalized name: Alfacalcidol 1 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microgram 1 alpha (OH)D3 daily + 300 mg elemental calcium
Trial: 9099188
Drug: Inactive placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive placebo + 300 mg elemental calcium
Trial: 8232358
Drug: Milacemide at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milacemide at a starting dose of 2,400 mg/day, increased to a maximum of 4,800 mg/day
Trial: 3552455
Drug: Lignocaine (5%)
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lignocaine (5%) spray
Trial: 3552455
Drug: Cinchocaine (2%)
RxNorm normalized name: cinchocaine
DrugBank: Cinchocaine (DB00527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cinchocaine (2%) spray
Trial: 3552455
Drug: Water-only placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water-only placebo spray
Trial: 31209271
Drug: Starved treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starved treatment (no food)
Trial: 31209271
Drug: Fed treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fed treatment (ad libitum access to food)
Trial: 25071343
Drug: Telbivudine (LDT,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine (LDT, 600 mg/d)
Trial: 25071343
Drug: Lamivudine (LAM,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine (LAM, 100 mg/d)
Trial: 24304478
Drug: Self-weighing twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-weighing twice a day with daily target setting and feedback (group 2)
Trial: 20679147
Drug: Fortified drinking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified drinking water with 7.5 mg of elemental iron per liter (group B)
Trial: 20679147
Drug: Fortified drinking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified drinking water with 10 mg of elemental iron per liter (group C)
Trial: 20679147
Drug: Fortified drinking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified drinking water with 5 mg of elemental iron per liter (group A)
Trial: 18806533
Drug: Ibandronate (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate (6 mg infusions administered on each of 3 days)
Trial: 12689976
Drug: Counselling on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counselling on physical activity (green prescription programme)
Trial: 10569217
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement (PerMamma Abbott) providing 20mg zinc sulfate, 2mg copper sulfate, and 116 microg potassium iodide.
Trial: 10569217
Drug: Traditional Italian
RxNorm normalized name: ALLERGENIC EXTRACT, ITALIAN RYEGRASS POLLEN
DrugBank: Lolium perenne subsp. multiflorum pollen (DB10964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Italian diet without vitamin and mineral supplements.
Trial: 9972143
Drug: Low-dose doxycycline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose doxycycline (LDD)
Trial: 1860094
Drug: Nitrendipine 10
RxNorm normalized name: nitrendipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine 10 mg once daily (increased to 20 mg if needed)
Trial: 17619207
Drug: Analgesics (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics (50 mg pethidine and 10 mg diazepam)
Trial: 15899018
Drug: Transmandibular implant-retained
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transmandibular implant-retained overdentures
Trial: 15899018
Drug: Four endosseous
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four endosseous implants following augmentation of the mandible
Trial: 15899018
Drug: Four short
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four short endosseous implants
Trial: 15899018
Drug: Laboratory-assessed masticatory
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laboratory-assessed masticatory function (before treatment)
Trial: 9583839
Drug: Small supplement
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small supplement (0.93 micromol beta‐carotene/d, first 60 days)
Trial: 9583839
Drug: Small supplement
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small supplement (0.93 micromol beta‐carotene/d, days 61-120)
Trial: 9583839
Drug: Larger mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larger mixed carotenoid supplement (6.16 micromol beta‐carotene/d, days 101-120)
Trial: 29745298
Drug: Experimental protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental protocol using TICCS for treatment guidance
Trial: 24314930
Drug: Tacrolimus Medis
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus Medis 5 mg
Trial: 24314930
Drug: Prograf® 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prograf® 5 mg